p53-Based Strategy to Reduce Hematological Toxicity of Chemotherapy: A Proof of Principle Study

P53 activation is a primary mechanism underlying pathological responses to DNA-damaging agents such as chemotherapy and radiotherapy. Our recent animal studies showed that low dose arsenic (LDA)-induced transient p53 inhibition selectively protected normal tissues from chemotherapy-induced toxicity.Study objectives were to: 1) define the lowest safe dose of arsenic trioxide that transiently blocks p53 activation in patients and 2) assess the potential of LDA to decrease hematological toxicity from chemotherapy.

Source: Molecular Oncology - September 17, 2015 Category: Cancer & Oncology Authors: Chul S. Ha, Joel E. Michalek, Richard Elledge, Kevin R. Kelly, Suthakar Ganapathy, Hang Su, Carol A. Jenkins, Athanassios Argiris, Ronan Swords, Tony Y. Eng, Anand Karnad, Richard L. Crownover, Gregory P. Swanson, Martin Goros, Brad H. Pollock, Zhi-Min Yu Source Type: research